The Oncolytic Adenovirus DNX-2401 Has Antitumor Activity in Glioblastoma [Clinical Trials]

In a phase I trial, DNX-2401 is safe and achieves durable responses in patients with recurrent glioma.

from Cancer via ola Kala on Inoreader https://ift.tt/2Jd1Vgn
via IFTTT